CL2017000664A1 - Micropartículas inyectables para la liberación hiper-localizada de agentes terapéuticos - Google Patents

Micropartículas inyectables para la liberación hiper-localizada de agentes terapéuticos

Info

Publication number
CL2017000664A1
CL2017000664A1 CL2017000664A CL2017000664A CL2017000664A1 CL 2017000664 A1 CL2017000664 A1 CL 2017000664A1 CL 2017000664 A CL2017000664 A CL 2017000664A CL 2017000664 A CL2017000664 A CL 2017000664A CL 2017000664 A1 CL2017000664 A1 CL 2017000664A1
Authority
CL
Chile
Prior art keywords
hyper
therapeutic agents
injectable microparticles
localized release
microparticles
Prior art date
Application number
CL2017000664A
Other languages
English (en)
Inventor
James A Helliwell
Amanda M Malone
Original Assignee
Eupraxia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eupraxia Pharmaceuticals Inc filed Critical Eupraxia Pharmaceuticals Inc
Publication of CL2017000664A1 publication Critical patent/CL2017000664A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>En el presente documento se describen micropartículas inyectables cargadas con fármaco, composición farmacéutica de las mismas y métodos para su uso en un compartimento corporal o para administración sistémica</p>
CL2017000664A 2014-09-19 2017-03-17 Micropartículas inyectables para la liberación hiper-localizada de agentes terapéuticos CL2017000664A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462052959P 2014-09-19 2014-09-19

Publications (1)

Publication Number Publication Date
CL2017000664A1 true CL2017000664A1 (es) 2018-03-02

Family

ID=55533935

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000664A CL2017000664A1 (es) 2014-09-19 2017-03-17 Micropartículas inyectables para la liberación hiper-localizada de agentes terapéuticos

Country Status (14)

Country Link
US (1) US20170246117A1 (es)
EP (1) EP3193847A4 (es)
JP (1) JP2017528527A (es)
KR (1) KR20170056573A (es)
CN (1) CN107106506A (es)
AU (1) AU2015317339A1 (es)
BR (1) BR112017005666A2 (es)
CA (1) CA2960860A1 (es)
CL (1) CL2017000664A1 (es)
IL (1) IL251216A0 (es)
MX (1) MX2017003638A (es)
RU (1) RU2017113354A (es)
SG (2) SG11201701870PA (es)
WO (1) WO2016044799A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015024234B1 (pt) 2013-03-21 2022-11-16 Eupraxia Pharmaceuticals USA LLC Composição farmacêutica de liberação sustentada injetável, uso da mesma para diminuir inflamação ou controlar dor e método para formar micropartículas revestidas
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
DK3206672T3 (en) 2015-10-27 2018-06-18 Eupraxia Pharmaceuticals Inc Formulations for sustained release of local anesthetics
WO2019071245A1 (en) 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. IMPLANTABLE DEPOSITS FOR REGULATED RELEASE OF ANALGESICS TO TREAT POSTHOPERATIVE PAIN ASSOCIATED WITH ORTHOPEDIC SURGERY, AND RELATED DEVICES, SYSTEMS, AND METHODS
CN116650732A (zh) 2018-01-08 2023-08-29 铸造疗法股份有限公司 经由治疗剂的控制递送用于治疗腔内癌症的装置、系统和方法
US12458589B2 (en) 2018-05-12 2025-11-04 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled release of therapeutic agents
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
MX2020012459A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
WO2020047013A1 (en) 2018-08-28 2020-03-05 Foundry Therapeutics, Inc. Polymer implants
US20220168665A1 (en) * 2019-04-10 2022-06-02 Eupraxia Pharmaceuticals Inc. Process for making drug crystals of desired size distribution and morphology
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
AU2024225341A1 (en) 2023-02-21 2025-09-04 Osteal Therapeutics, Inc. Methods of treating a localized infection with locally administered antibiotics
US20240424000A1 (en) * 2023-06-26 2024-12-26 Eupraxia Pharmaceuticals Inc. Long-acting intra-articular dosage forms containing fluticasone propionate and use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568559A (en) * 1984-02-06 1986-02-04 Biotek, Inc. Composite core coated microparticles and process of preparing same
US5922340A (en) * 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
GB0027357D0 (en) * 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
US20030152637A1 (en) * 2001-01-25 2003-08-14 Mark Chasin Local anesthetic, and method of use
EP1585500B8 (en) * 2002-12-20 2017-07-26 Auritec Pharmaceuticals Coated particles for sustained-release pharmaceutical administration
US20040191326A1 (en) * 2003-03-31 2004-09-30 Reo Joseph P. Taste-masking vehicle for coated oxazolidinone particles
EA008771B1 (ru) * 2003-07-31 2007-08-31 Сол-Джел Текнолоджиз Лтд. Микрокапсулы, заполненные активными ингредиентами, и способ их приготовления
UA96342C2 (en) * 2007-06-25 2011-10-25 Оцука Фармасьютикал Ко., Лтд. Microspheres having core/shell structure
US8846068B2 (en) * 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
KR101423237B1 (ko) * 2010-05-04 2014-07-30 주식회사 삼양바이오팜 탐스로신 또는 이의 약학적으로 허용 가능한 염을 포함하는 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
JP5222917B2 (ja) * 2010-09-21 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
CN102070895B (zh) * 2010-11-17 2013-03-27 无锡中科光远生物材料有限公司 一种核壳结构微胶囊及其制备方法
JP6083936B2 (ja) * 2011-03-11 2017-02-22 大阪ガスケミカル株式会社 徐放性粒子の製造方法
BR112014010782A2 (pt) * 2011-11-03 2017-06-13 Gtx Inc composições farmacêuticas de moduladores de receptor de androgênio seletivos e aplicações das mesmas
CN104159635B (zh) * 2012-02-27 2018-09-25 奥雷制药有限公司 用于耳蜗内递送治疗剂以治疗耳部病症的固体药物植入物
BR112015024234B1 (pt) * 2013-03-21 2022-11-16 Eupraxia Pharmaceuticals USA LLC Composição farmacêutica de liberação sustentada injetável, uso da mesma para diminuir inflamação ou controlar dor e método para formar micropartículas revestidas

Also Published As

Publication number Publication date
EP3193847A4 (en) 2018-06-06
RU2017113354A (ru) 2018-10-19
CA2960860A1 (en) 2016-03-24
RU2017113354A3 (es) 2019-04-18
WO2016044799A1 (en) 2016-03-24
JP2017528527A (ja) 2017-09-28
US20170246117A1 (en) 2017-08-31
IL251216A0 (en) 2017-05-29
SG11201701870PA (en) 2017-04-27
AU2015317339A1 (en) 2017-04-27
KR20170056573A (ko) 2017-05-23
EP3193847A1 (en) 2017-07-26
SG10201902407PA (en) 2019-04-29
BR112017005666A2 (pt) 2017-12-19
CN107106506A (zh) 2017-08-29
MX2017003638A (es) 2017-11-08

Similar Documents

Publication Publication Date Title
CL2017000664A1 (es) Micropartículas inyectables para la liberación hiper-localizada de agentes terapéuticos
CL2014003444A1 (es) Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes.
AR094867A1 (es) Conjugados de anticuerpos y sus usos
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
MX2022004374A (es) Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cancer.
HUE057877T2 (hu) Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
BR112018070199A2 (pt) composição farmacêutica de hormônio esteroide
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
DK3283158T3 (da) Lægemiddelindgivelsesindretning med separerbare mikronåle
CL2015002335A1 (es) Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas.
BR112018010671A8 (pt) dispositivos e métodos de distribuição de fármaco com mudança de forma
EP3463429A4 (en) PARTIAL INSULIN RECEPTOR AGONISTS AND GLP-1 ANALOGUES
CL2016000556A1 (es) Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso.
HUE054587T2 (hu) In vivo gyógyszerbejuttató eszközök
LT3324948T (lt) Daugiasluoksnės farmaciniu požiūriu aktyvaus junginio atpalaidavimo mikrodalelės skystoje vaisto formoje
MX381016B (es) Composiciones de nanopartículas para su uso en la entrega de una carga útil al cerebro.
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
MX389178B (es) Formulacion de proporcion fija de insulina glargina/lixisenatida.
CO2018012180A2 (es) Métodos de tratamiento para enfermedades colestásicas y fibróticas
IL265677A (en) Formulation of a controlled-release ophthalmic drug and its uses
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
CO2017010692A2 (es) Construcciones de calicheamicina y sus métodos de uso